Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
Status: | Completed |
---|---|
Conditions: | Renal Impairment / Chronic Kidney Disease |
Therapuetic Areas: | Nephrology / Urology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | September 2011 |
End Date: | July 2012 |
Randomized,Multi-center,Phase IV, 2-arm,Open-Label,Cross-over Study to Demonstrate the Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
The purpose of this study is to demonstrate equivalence of calcium acetate oral solution and
sevelamer carbonate in maintaining serum phosphorus levels
This is a phase IV, multicenter, randomized, open-label, cross-over study to assess the
equivalence of a liquid formulation of a calcium-based phosphate binder, COS, to sevelamer
carbonate tablets, in hemodialysis dependent Chronic Kidney Disease subjects (CKD). The aim
of the study is to maintain serum phosphorus level and establish equivalence between COS and
sevelamer carbonate tablets.
sevelamer carbonate in maintaining serum phosphorus levels
This is a phase IV, multicenter, randomized, open-label, cross-over study to assess the
equivalence of a liquid formulation of a calcium-based phosphate binder, COS, to sevelamer
carbonate tablets, in hemodialysis dependent Chronic Kidney Disease subjects (CKD). The aim
of the study is to maintain serum phosphorus level and establish equivalence between COS and
sevelamer carbonate tablets.
Total 40 subjects will be randomized for participation into the study The subjects are
Hemo-dialysis Dependent Chronic Kidney Disease (CKD) Stage 5D patients who are able to give
informed consent to the study, and taking the phosphate binder sevelamer carbonate tablets.
Hemo-dialysis Dependent Chronic Kidney Disease (CKD) Stage 5D patients who are able to give
informed consent to the study, and taking the phosphate binder sevelamer carbonate tablets.
Inclusion Criteria:
- Male or female subjects ≥18 years of age able to give written informed consent to the
study
- Hemodialysis dependent chronic kidney disease stage 5D patients
- Taking sevelamer carbonate tablets or sevelamer hydrochloride as phosphate binder
monotherapy
- Taking 3 or more sevelamer carbonate or sevelamer hydrochloride tablets per day
Exclusion Criteria:
- Estimated life expectancy of less than 6 months and for cancer patients, an Eastern
Cooperative Oncology Group (ECOG) Performance Status >1
- Active malignancy within the past 5 years. Basal or squamous cell skin cancer is not
exclusionary. History of malignancy is not an exclusion
- Known hypersensitivity reaction to calcium-based phosphate binders
- Anticipated renal transplantation during the study
- Pregnant or sexually active female subjects who are of childbearing potential and who
are not willing to use an acceptable form of contraception.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials